Blockers of PCSK9 Ribosome Synthesis: Computational Predictions and in Vitro Confirmation

Keyphrases

• Beta-blockers 100%
• Computational Prediction 100%
• Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) 100%
• Ribosome Synthesis 100%
• LDL Receptor 45%
• Incubation 18%
• IC50 18%
• Protein Data Bank 18%
• Inhibition Rate 18%
• Spent Medium 18%
• Nine-level 18%
• Exit Channel 18%
• Small Molecules 9%
• Conformational Change 9%
• Monoclonal Antibody 9%
• Negative Effects 9%
• Cell Surface 9%
• Extracellular Space 9%
• Toxic Chemicals 9%
• Hypercholesterolemia 9%
• Endocytosis 9%
• Surface Density 9%
• Receptor Cells 9%
• Ribosomal RNA 9%
• Binding Energy 9%
• Lysosome 9%
• FDA-approved Drugs 9%
• Stall 9%
• Blood Levels 9%
• Propeptide 9%
• In Vitro Testing 9%
• Secretagogue 9%
• Receptor Recycling 9%
• Applicability Domain 9%
• Cell Mortality 9%
• Huh7 Cells 9%
• Ribosome Stalling 9%
• Proprotein Convertase 9%
• Bank Structure 9%
• MTS Assay 9%
• Endoproteinase 9%
• Selectivity Index 9%
• Cell Confluence 9%

Biochemistry, Genetics and Molecular Biology

• Subtilisin 100%
• Kexin 100%
• Proprotein Convertase 100%
• LDL Receptor 41%
• IC50 16%
• Protein Data Bank 16%
• Conformational Change 8%
• Maturation 8%
• Secretion (Process) 8%
• Blood Level 8%
• Hypercholesterolemia 8%
• Endocytosis 8%
• Lysosome 8%
• Binding Energy 8%
• Monoclonal Antibody 8%
• Small Molecule 8%
• Selectivity Index 8%
• Ribosomal RNA 8%